Literature DB >> 24933605

BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.

Celeste Lebbé1, Alexandre How-Kit, Maxime Battistella, Aurelie Sadoux, Marie-Pierre Podgorniak, Irina Sidina, Cécile Pages, Jennifer Roux, Raphael Porcher, Jorg Tost, Samia Mourah.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24933605     DOI： 10.1097/CMR.0000000000000088

Source DB:  PubMed          Journal:  Melanoma Res        ISSN： 0960-8931            Impact factor:   3.599


× No keyword cloud information.
  10 in total

1.  E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.

Authors:  Hani M Babiker; Sara A Byron; William P D Hendricks; William F Elmquist; Gautham Gampa; Jessica Vondrak; Jessica Aldrich; Lori Cuyugan; Jonathan Adkins; Valerie De Luca; Raoul Tibes; Mitesh J Borad; Katie Marceau; Thomas J Myers; Linda J Paradiso; Winnie S Liang; Ronald L Korn; Derek Cridebring; Daniel D Von Hoff; John D Carpten; David W Craig; Jeffrey M Trent; Michael S Gordon
Journal:  Invest New Drugs       Date:  2018-09-28       Impact factor: 3.850

2.  Variations of BRAF mutant allele percentage in melanomas.

Authors:  Zofia Hélias-Rodzewicz; Elisa Funck-Brentano; Laure Baudoux; Chan Kwon Jung; Ute Zimmermann; Cristi Marin; Thierry Clerici; Catherine Le Gall; Frédérique Peschaud; Valérie Taly; Philippe Saiag; Jean-François Emile
Journal:  BMC Cancer       Date:  2015-07-04       Impact factor: 4.430

3.  Variation of mutant allele frequency in NRAS Q61 mutated melanomas.

Authors:  Zofia Hélias-Rodzewicz; Elisa Funck-Brentano; Nathalie Terrones; Alain Beauchet; Ute Zimmermann; Cristi Marin; Philippe Saiag; Jean-François Emile
Journal:  BMC Dermatol       Date:  2017-07-01

4.  Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.

Authors:  V Doma; S Kárpáti; E Rásó; T Barbai; J Tímár
Journal:  BMC Cancer       Date:  2019-08-07       Impact factor: 4.430

5.  Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care.

Authors:  Baptiste Louveau; Fanelie Jouenne; Coralie Reger de Moura; Aurelie Sadoux; Barouyr Baroudjian; Julie Delyon; Florian Herms; Adele De Masson; Laetitia Da Meda; Maxime Battistella; Nicolas Dumaz; Celeste Lebbe; Samia Mourah
Journal:  Cancers (Basel)       Date:  2019-08-18       Impact factor: 6.639

6.  Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers.

Authors:  Priyanka Gopal; Elif Irem Sarihan; Eui Kyu Chie; Gwendolyn Kuzmishin; Semihcan Doken; Nathan A Pennell; Daniel P Raymond; Sudish C Murthy; Usman Ahmad; Siva Raja; Francisco Almeida; Sonali Sethi; Thomas R Gildea; Craig D Peacock; Drew J Adams; Mohamed E Abazeed
Journal:  Nat Commun       Date:  2019-11-13       Impact factor: 14.919

7.  BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.

Authors:  Arrate Sevilla; M Celia Morales; Pilar A Ezkurra; Javier Rasero; Verónica Velasco; Goikoane Cancho-Galan; Ana Sánchez-Diez; Karmele Mujika; Cristina Penas; Isabel Smith; Aintzane Asumendi; Jesús M Cortés; Maria Dolores Boyano; Santos Alonso
Journal:  PLoS One       Date:  2020-03-13       Impact factor: 3.240

8.  Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma.

Authors:  Coralie Reger de Moura; Laetitia Vercellino; Fanélie Jouenne; Barouyr Baroudjian; Aurélie Sadoux; Baptiste Louveau; Julie Delyon; Kevin Serror; Lauriane Goldwirt; Pascal Merlet; Fanny Bouquet; Maxime Battistella; Céleste Lebbé; Samia Mourah
Journal:  Transl Oncol       Date:  2019-12-23       Impact factor: 4.243

Review 9.  Intratumor and Intertumor Heterogeneity in Melanoma.

Authors:  Tomasz M Grzywa; Wiktor Paskal; Paweł K Włodarski
Journal:  Transl Oncol       Date:  2017-10-24       Impact factor: 4.243

10.  BRAF V600 mutation profiling in primary skin nodular melanoma in Indonesia: an analysis using high resolution pyrosequencing.

Authors:  Hanggoro Tri Rinonce; Rovi Panji Mustiko Aji; Ni'mah Hayati; Maria Fransiska Pudjohartono; Bidari Kameswari; Sumadi Lukman Anwar
Journal:  BMC Res Notes       Date:  2020-03-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.